Document Preview Unavailable

Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review

Sutherland Duncan E K; Kashyap Raghava; Price, Jackson; Buteau, James P; Murphy, Declan G; et al.  Therapeutic Advances in Medical Oncology Vol. 15,  (Jan 2023).

You might have access to this document